Below is a selection of journal articles and reports which are about pharmaceuticals, prescribing, and overprescribing in healthcare. If you are looking to answer a specific question please submit a literature search request at the link above. If you would like to be alerted when new content is available here then please sign in and select Follow. You are welcome to leave comments and suggestions below in the comments section.
Berdud, M., Chalkidou, K., Dean, E. (2019) The future of global health procurement: Issues around pricing transparency. The Office of Health Economics
This OHE Research Paper focuses on the role that price trasnparency may pleay in the efficient and effective procurement of medicines by middle and low income countries. Will making prices publicly avaialble make procurement more efficien and cose effective medicines more accessible?
IHI Blog, Leslie Pelton, September 10 2018. Describing can mean fewer Opioids, more grateful patients (last accessed 19/10/2018).
Chalmers, D., Poole, C., Webster, S., et al (2018) Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational stidy using the Clinical Practice Research Datalink (CRPD). Respiratory Research 19(1):63
Conclusion: The data suggests that ICS use in GOLD A and B COPD patients is not associated with a benefit in terms of healthcare resource use compared to non-ICS bronchodilator based therapy; using ICS according to GOLD recommendations may offer an opportunity for improving patient care and reducing resource use
Greise-Mammen, N., Heisberger, KE., Meeerlie, M., et al (2018) PCNE definition of medication review: reaching agreement. International Journal of Clinical Pharmacy 40(5): 1199-1208.
Conclusion: Involvment of an international community from research and practice and use of a systematic process led to an afreement on the term medication review and on classification valide for all settings and professions.
Miani, C., Martin, A., Exley, J., et al. (2017) Clinical effectiveness and cost-effectiveness of issuing longer versis shorter duration (3 months vrs 28 day) prescriptions in patients with chronic conditions: systematic review and economic modelling. Health Technology Assessment 21 (78): 1-128. Although the quality of evidence was poor, this study found that longer prescriptions may be less costly overall, and may be assoicated with better adherence than 28 day prescriptions in patients with chronic conditions in primary care.
McCarthy D. Reducing Inappropriate Medication Use by Implementing Deprescribing Guidelines. Cambridge, Massachusetts: Institute for Healthcare Improvement; 2017.
A multidisciplinary team of clinical experts in Ottawa, Canada, created a credible, low-cost process for developing and implementing evidence-based deprescribing guidelines and tools for assessing, tapering, and stopping medications that may cause harm or no longer benefit patients. Although the guidelines led primary care teams to consider approaches for identifying such medications and engaging patients in conversations about discontinuing them, the intervention has thus far been more successful in long-term care settings, where it strengthened team-based medication reviews in fulfillment of routine quality improvement and reporting requirements.
For more information and to obtain the full text click here.
Public Health England, 2015. Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England. Public Health England, July 2015 (last accessed 11/09/2015)
“Comparison with epidemiological studies of mental illness in adults with learning disabilities suggests that 13% of the population (roughly 23,800 people) are being prescribed antipsychotics in the absence of a psychotic illness, and 10% antidepressants in the absence of an affective illness
(roughly 19,500 people). Allowing for overlap, which is common, we estimate that between 30,000 and 35,000 adults with a learning disability in England are taking one or both of these types of drug
in the absence of the conditions for which they are indicated. Prescribing of antipsychotics and antidepressants to children and young people is much less common.” (page 6-7)